Liquidia (NASDAQ:LQDA) Downgraded to Strong Sell Rating by Zacks Research

Posted by Stanley Muller on Sep 24th, 2026

Liquidia (NASDAQ:LQDA – Get Free Report) was downgraded by research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued to clients and investors on Tuesday, Zacks reports.

Several other equities analysts have also weighed in on LQDA. Wells Fargo & Company lifted their price target on Liquidia from $62.00 to $108.00 and gave the company an “overweight” rating in a research note on Thursday, August 13th. Wall Street Zen raised shares of Liquidia from a “hold” rating to a “buy” rating in a research report on Sunday. Weiss Ratings raised Liquidia from a “sell (d-)” rating to a “hold (c)” rating in a report on Tuesday. Lifesci Capital downgraded Liquidia from an “outperform” rating to a “hold” rating and set a $90.00 price target for the company. in a report on Wednesday, August 12th. Finally, BTIG Research upped their price objective on Liquidia from $109.00 to $111.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Liquidia presently has an average rating of “Hold” and a consensus target price of $98.08.

Read Our Latest Report on LQDA

Liquidia Price Performance

Liquidia stock opened at $67.49 on Tuesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.31 and a quick ratio of 2.12. The stock has a market cap of $6.04 billion, a price-to-earnings ratio of 49.26 and a beta of 0.53. The firm has a 50-day moving average of $75.72 and a two-hundred day moving average of $61.42. Liquidia has a 1 year low of $21.15 and a 1 year high of $93.61.

Liquidia (NASDAQ:LQDA – Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%.The firm had revenue of $171.68 million for the quarter, compared to analysts’ expectations of $168.48 million. During the same quarter in the previous year, the business earned ($0.49) earnings per share. The company’s revenue for the quarter was up 1842.1% compared to the same quarter last year. On average, research analysts forecast that Liquidia will post 2.57 earnings per share for the current year.

Insider Activity

In related news, CEO Roger Jeffs sold 35,249 shares of the stock in a transaction on Monday, July 13th. The shares were sold at an average price of $71.51, for a total transaction of $2,520,655.99. Following the completion of the sale, the chief executive officer owned 1,130,426 shares in the company, valued at $80,836,763.26. This represents a 3.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Rajeev Saggar sold 50,000 shares of Liquidia stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $74.06, for a total transaction of $3,703,000.00. Following the completion of the transaction, the insider owned 142,265 shares in the company, valued at approximately $10,536,145.90. This represents a 26.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 622,519 shares of company stock worth $48,078,514 over the last ninety days. 25.60% of the stock is owned by corporate insiders.

Institutional Trading of Liquidia

A number of hedge funds have recently added to or reduced their stakes in LQDA. WINTON GROUP Ltd purchased a new position in shares of Liquidia in the 2nd quarter valued at approximately $335,000. Arizona State Retirement System increased its stake in Liquidia by 5.4% in the 2nd quarter. Arizona State Retirement System now owns 17,627 shares of the company’s stock valued at $1,405,000 after buying an additional 900 shares during the period. Nykredit A S acquired a new position in Liquidia in the 2nd quarter valued at $177,000. Corient Private Wealth LP purchased a new position in Liquidia during the 2nd quarter worth $758,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Liquidia in the 2nd quarter worth $1,236,000. 64.54% of the stock is owned by institutional investors and hedge funds.

About Liquidia

(Get Free Report)

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious cardiopulmonary conditions, including pulmonary arterial hypertension (PAH). The company is headquartered in Research Triangle Park, North Carolina, and serves healthcare providers and patients primarily in the United States.

Liquidia’s lead product is Yutrepia, an inhaled formulation of treprostinil designed for the treatment of PAH. The company has also developed treprostinil injection products and is pursuing additional therapies for rare cardiopulmonary diseases.